A systematic review and cost-effectiveness analysis of specialist services and adrenaline auto-injectors in anaphylaxis

Autor: N Armstrong, R Wolff, G van Mastrigt, N Martinez, AV Hernandez, K Misso, J Kleijnen

Publikováno v: Health Technology Assessment, Vol 17, Iss 17 (2013)

Background: Anaphylaxis is a severe, life-threatening generalised or systemic hypersensitivity reaction with high mortality. Specialist services (SSs) are believed to reduce anaphylaxis recurrence and improve use of adrenaline injectors (AIs), which

Externí odkaz: https://doaj.org/article/5d4c2bf0404a4f0a98fe8f46dd671e4a

Triglyceride-glucose index as a predictor of cardiac adverse events in acute coronary syndrome patients undergoing percutaneous coronary intervention: role of diabetes.

Autor: Khalaji A; Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.; Cardiovascular Diseases Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.; School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.; Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran., Behnoush AH; Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.; Cardiovascular Diseases Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.; School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.; Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran., Pasebani Y; Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.; Cardiovascular Diseases Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.; Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran., Rafati A; Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.; Cardiovascular Diseases Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.; Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran., Mahmoodi T; Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.; Cardiovascular Diseases Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran., Arzhangzadeh A; Department of Cardiology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran., Shamshiri Khamene S; Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.; Cardiovascular Diseases Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran., MohammadKhawajah I; Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.; Cardiovascular Diseases Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran., Mehrani M; Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.; Cardiovascular Diseases Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran., Vasheghani-Farahani A; Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.; Cardiovascular Diseases Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran., Masoudkabir F; Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.; Cardiovascular Diseases Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran., Najafi K; Hakim Children Hospital, Tehran University of Medical Sciences, Tehran, Iran., Askari MK; Department of Medicine, The University of Toledo Medical Center, Toledo, USA., Harrison A; Internal Medicine, University of Central Florida/HCA Florida West Hospital, Pensacola, USA., Nelson JR; California Cardiovascular Institute, 7061 N. Whitney, Suite 101, Fresno, CA, 93720, USA., Hosseini K; Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran. kaveh_hosseini130@yahoo.com.; Cardiovascular Diseases Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. kaveh_hosseini130@yahoo.com., Hernandez AV; Health Outcomes, Policy, and Evidence Synthesis (HOPES) Group, University of Connecticut School of Pharmacy, Storrs, CT, USA.; Vicerrectorado de Investigación, Unidad de Revisiones Sistemáticas y Meta-análisis (URSIGET), Universidad San Ignacio de Loyola, Lima, Peru.

Publikováno v: BMC cardiovascular disorders [BMC Cardiovasc Disord] 2024 Sep 27; Vol. 24 (1), pp. 514. Date of Electronic Publication: 2024 Sep 27.

Efficacy and safety of ivermectin for treatment of non-hospitalized COVID-19 patients: A systematic review and meta-analysis of 12 randomized controlled trials with 7,035 participants.

Autor: Hernandez AV; Health Outcomes, Policy, and Evidence Synthesis (HOPES) Group, University of Connecticut School of Pharmacy, Storrs, CT, USA; Vicerrectorado de Investigación, Universidad San Ignacio de Loyola (USIL), Lima, Peru. Electronic address: adrian.hernandez-diaz@uconn.edu., Liu A; Health Outcomes, Policy, and Evidence Synthesis (HOPES) Group, University of Connecticut School of Pharmacy, Storrs, CT, USA., Roman YM; Health Outcomes, Policy, and Evidence Synthesis (HOPES) Group, University of Connecticut School of Pharmacy, Storrs, CT, USA., Burela PA; Facultad de Salud Pública y Administración, Universidad Peruana Cayetano Heredia, Lima, Peru., Pasupuleti V; Oxford PharmaGenesis, Inc., Newtown, PA, USA., Thota P; Hemex Health, Inc. Portland, OR, USA., Carranza-Tamayo CO; Faculdade de Medicina, Universidade Católica de Brasilia, Taguatinga, Brasília-DF, Brazil., Retamozo-Palacios M; Department of Infectious Diseases, Hospital Regional de Taguatinga, Taguatinga, Brasília-DF, Brazil., Benites-Zapata VA; Master Program in Clinical Epidemiology and Biostatistics, Universidad Científica del Sur, Lima, Peru., Piscoya A; Servicio de Gastroenterología, Departamento de Medicina, Hospital Guillermo Kaelin de la Fuente, Lima, Peru., Vidal JE; Division of Infectious Diseases, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil; Department of Neurology, Instituto de Infectologia Emílio Ribas, São Paulo, Brazil; Laboratory of Medical Investigation, Unit 49, Hospital das Clinicas, Universidade de São Paulo, São Paulo, Brazil.

Publikováno v: International journal of antimicrobial agents [Int J Antimicrob Agents] 2024 Aug; Vol. 64 (2), pp. 107248. Date of Electronic Publication: 2024 Jun 20.

Early safety and efficiency outcomes of a novel interdisciplinary laparoscopic resection rectopexy combined with sacrocolpopexy for women with obstructive defecation syndrome and pelvic organ prolapse: a single center study.

Autor: Rudroff C; Department of Visceral Surgery and Functional Surgery of the Lower Gastrointestinal Tract (UGI), Clinic for General and Visceral Surgery, Evangelisches Klinikum Köln Weyertal GmbH, Academic Hospital of the University of Cologne, Weyertal 76, Cologne, 50931, Germany. claudia@rudroff.com., Madukkakuzhy J; Department of Visceral Surgery and Functional Surgery of the Lower Gastrointestinal Tract (UGI), Clinic for General and Visceral Surgery, Evangelisches Klinikum Köln Weyertal GmbH, Academic Hospital of the University of Cologne, Weyertal 76, Cologne, 50931, Germany., Hernandez AV; Department of Visceral Surgery and Functional Surgery of the Lower Gastrointestinal Tract (UGI), Clinic for General and Visceral Surgery, Evangelisches Klinikum Köln Weyertal GmbH, Academic Hospital of the University of Cologne, Weyertal 76, Cologne, 50931, Germany.; Department of General, Visceral and Minimally Invasive Surgery, Park-Klinik Weissensee Berlin, Berlin, Germany., Otten J; Department of Visceral Surgery and Functional Surgery of the Lower Gastrointestinal Tract (UGI), Clinic for General and Visceral Surgery, Evangelisches Klinikum Köln Weyertal GmbH, Academic Hospital of the University of Cologne, Weyertal 76, Cologne, 50931, Germany.; Department of Oral, Maxillofacial and Plastic Surgery, University Hospital Bonn, Bonn, Germany., Ulrici C; Department of Visceral Surgery and Functional Surgery of the Lower Gastrointestinal Tract (UGI), Clinic for General and Visceral Surgery, Evangelisches Klinikum Köln Weyertal GmbH, Academic Hospital of the University of Cologne, Weyertal 76, Cologne, 50931, Germany.; Department of General and Visceral Surgery, St.Josef Hospital Bonn-Beuel, GFO Kliniken Bonn, Bonn, Germany., Karapanos L; Department of Urology, Division of Neurourology, University Hospital of Cologne and Medical Faculty Cologne, 50931, Cologne, Germany.; Department of Urology, Municipal Hospital of Leverkusen, Leverkusen, Germany., Ludwig S; Department of Obstetrics and Gynecology, Division of Urogynecology and Pelvic Reconstructive Surgery, University Hospital of Cologne and Medical Faculty Cologne, 50931, Cologne, Germany.

Publikováno v: BMC surgery [BMC Surg] 2024 Jun 14; Vol. 24 (1), pp. 185. Date of Electronic Publication: 2024 Jun 14.

Andexanet alfa versus PCC products for factor Xa inhibitor bleeding: A systematic review with meta-analysis.

Autor: White CM; University of Connecticut School of Pharmacy, Storrs, Connecticut, USA.; Hartford Hospital Health Outcomes, Policy and Evidence Synthesis Group, Hartford, Connecticut, USA., Caroti KS; University of Connecticut School of Pharmacy, Storrs, Connecticut, USA.; Hartford Hospital Health Outcomes, Policy and Evidence Synthesis Group, Hartford, Connecticut, USA., Bessada Y; University of Connecticut School of Pharmacy, Storrs, Connecticut, USA., Hernandez AV; University of Connecticut School of Pharmacy, Storrs, Connecticut, USA.; Hartford Hospital Health Outcomes, Policy and Evidence Synthesis Group, Hartford, Connecticut, USA.; Unidad de Revisiones Sistemáticas y Meta-análisis (URSIGET), Vicerrectorado de Investigación, Universidad San Ignacio de Loyola, Lima, Peru., Baker WL; University of Connecticut School of Pharmacy, Storrs, Connecticut, USA.; Hartford Hospital Health Outcomes, Policy and Evidence Synthesis Group, Hartford, Connecticut, USA., Dobesh PP; University of Nebraska Medical Center College of Pharmacy, Omaha, Nebraska, USA., van Haalen H; Health Economics & Payer Evidence, AstraZeneca, Gothenburg, Sweden., Rhodes K; Medical and Payer Evidence, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK., Coleman CI; University of Connecticut School of Pharmacy, Storrs, Connecticut, USA.; Hartford Hospital Health Outcomes, Policy and Evidence Synthesis Group, Hartford, Connecticut, USA.

Publikováno v: Pharmacotherapy [Pharmacotherapy] 2024 May; Vol. 44 (5), pp. 394-408. Date of Electronic Publication: 2024 May 09.